WO2001089520A3 - Dehydroascorbic acid formulations and uses thereof - Google Patents

Dehydroascorbic acid formulations and uses thereof Download PDF

Info

Publication number
WO2001089520A3
WO2001089520A3 PCT/US2000/041407 US0041407W WO0189520A3 WO 2001089520 A3 WO2001089520 A3 WO 2001089520A3 US 0041407 W US0041407 W US 0041407W WO 0189520 A3 WO0189520 A3 WO 0189520A3
Authority
WO
WIPO (PCT)
Prior art keywords
dehydroascorbic acid
acid formulations
conditions
treatment
dehydroascorbic
Prior art date
Application number
PCT/US2000/041407
Other languages
French (fr)
Other versions
WO2001089520A2 (en
Inventor
William C Olson
Robert J Israel
Thomas A Boyd
Original Assignee
Progenics Pharm Inc
William C Olson
Robert J Israel
Thomas A Boyd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenics Pharm Inc, William C Olson, Robert J Israel, Thomas A Boyd filed Critical Progenics Pharm Inc
Priority to AU2001222986A priority Critical patent/AU2001222986A1/en
Priority to EP00986812A priority patent/EP1282416A2/en
Priority to JP2001585764A priority patent/JP2004514650A/en
Priority to CA002408562A priority patent/CA2408562A1/en
Publication of WO2001089520A2 publication Critical patent/WO2001089520A2/en
Publication of WO2001089520A3 publication Critical patent/WO2001089520A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

The invention provides improved dehydroascorbic acid compositions and methods for treatment of medical conditions. The dehydroascorbic acid compositions are useful in the treatment of a variety of conditions which benefit from increased dehydroascorbic acid or ascorbic acid concentrations in tissues affected by the conditions.
PCT/US2000/041407 2000-05-19 2000-10-20 Dehydroascorbic acid formulations and uses thereof WO2001089520A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2001222986A AU2001222986A1 (en) 2000-05-19 2000-10-20 Dehydroascorbic acid formulations and uses thereof
EP00986812A EP1282416A2 (en) 2000-05-19 2000-10-20 Dehydroascorbic acid formulations and uses thereof
JP2001585764A JP2004514650A (en) 2000-05-19 2000-10-20 Dehydroascorbic acid formulations and uses thereof
CA002408562A CA2408562A1 (en) 2000-05-19 2000-10-20 Dehydroascorbic acid formulations and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20587000P 2000-05-19 2000-05-19
US60/205,870 2000-05-19

Publications (2)

Publication Number Publication Date
WO2001089520A2 WO2001089520A2 (en) 2001-11-29
WO2001089520A3 true WO2001089520A3 (en) 2002-09-12

Family

ID=22763983

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/041407 WO2001089520A2 (en) 2000-05-19 2000-10-20 Dehydroascorbic acid formulations and uses thereof

Country Status (5)

Country Link
EP (1) EP1282416A2 (en)
JP (1) JP2004514650A (en)
AU (1) AU2001222986A1 (en)
CA (1) CA2408562A1 (en)
WO (1) WO2001089520A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9308234B2 (en) 2012-10-29 2016-04-12 The University Of North Carolina At Chapel Hill Methods and compositions for treating mucosal tissue disorders

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1749552A1 (en) * 2005-07-29 2007-02-07 Neuropharma S.A. Use of collismycin and derivatives thereof as oxidative stress inhibitors
WO2009111681A2 (en) * 2008-03-07 2009-09-11 Lawrence Bernstein Gallium compounds and methods of use to treat inflammatory bowel disease
US8835506B2 (en) 2008-06-05 2014-09-16 Stc.Unm Methods and related compositions for the treatment of cancer
US9101537B2 (en) 2008-07-25 2015-08-11 Reven Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
NL2004260C2 (en) * 2010-02-18 2011-08-22 Univ Amsterdam Disinfectant composition and its use in dental treatment.
CN104997803B (en) 2010-07-22 2019-07-09 雷文制药有限公司 Comprising the treatment using magnetic dipole stabilizing solutions or improves disease and enhance the method and composition of performance
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
IL310203A (en) 2015-12-02 2024-03-01 Nippon Shinyaku Co Ltd Pharmaceutical composition containing 2-{4n-(5,6- diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n- (methylsulfonyl)acetamide
AU2017362500A1 (en) 2016-11-17 2019-06-13 Renovion, Inc. Treatment of Respiratory Tract Diseases and Infections with Ascorbic Acid Compositions
RU2693627C2 (en) * 2017-11-03 2019-07-03 Общество С Ограниченной Ответственностью "Валента - Интеллект" Edaravon combination for treating ischemic brain injury
AU2018367674A1 (en) 2017-11-17 2020-06-04 Renovion, Inc. Stable ascorbic acid compositions and methods of using the same
MX2020005879A (en) * 2017-12-07 2020-10-07 Reven Ip Holdco Llc Compositions and methods for the treatment of metabolic conditions.
EP3852529A4 (en) * 2018-09-17 2021-10-27 Smithers-Oasis Company Composition and method for improving the drought tolerance of plants
WO2021183705A1 (en) * 2020-03-11 2021-09-16 Siess Harold E Detection and treatment of viral diseases and cancer
CN115316375B (en) * 2022-08-15 2023-08-18 四川大学华西医院 Integrated puncture perfusion catheter for perfusion of abdominal organ transplantation donor

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2845484A1 (en) * 1978-10-19 1980-04-30 Groening Ruediger Inhibiting gastrointestinal degradation of medicaments - by co:administration of additives undergoing sacrificial degradation
GB2080681A (en) * 1980-07-24 1982-02-10 Miller Ercell L Oral compositions
EP0326826A1 (en) * 1988-02-03 1989-08-09 LEOPOLD PHARMA GESELLSCHAFT m.b.H. Medicine with a destructive effect on malignant tumours, process for its manufacture and preparation for use in the therapy of cancer patients
US5021452A (en) * 1989-01-09 1991-06-04 The Board Of Regents Of The University Of Washington Process for enhancing wound healing
US5070085A (en) * 1987-04-10 1991-12-03 Oxycal Laboratories, Inc. Compositions and methods for administering therapeutically active compounds
US5281196A (en) * 1992-05-22 1994-01-25 Sultenfuss Thomas J Skin treatment composition and method of use
WO1998052560A1 (en) * 1997-05-21 1998-11-26 Sloan-Kettering Institute For Cancer Research Method for increasing the concentration of ascorbic acid in brain tissues of a subject
DE19935763A1 (en) * 1999-07-27 2001-02-08 Volkhard Jenning Retinoid-containing emulsion for topical cosmetic or dermatological use, e.g. in skin regeneration or acne treatment, containing stabilizing combination of ascorbic acid and polyphenol compounds
WO2001015692A1 (en) * 1999-08-30 2001-03-08 Oxycal Laboratories, Inc. Methods and compositions for selective cancer chemotherapy
WO2001037830A1 (en) * 1999-11-24 2001-05-31 Sloan-Kettering Institute For Cancer Research Method for increasing the concentration of ascorbic acid in brain tissues of a subject

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2845484A1 (en) * 1978-10-19 1980-04-30 Groening Ruediger Inhibiting gastrointestinal degradation of medicaments - by co:administration of additives undergoing sacrificial degradation
GB2080681A (en) * 1980-07-24 1982-02-10 Miller Ercell L Oral compositions
US5070085A (en) * 1987-04-10 1991-12-03 Oxycal Laboratories, Inc. Compositions and methods for administering therapeutically active compounds
EP0326826A1 (en) * 1988-02-03 1989-08-09 LEOPOLD PHARMA GESELLSCHAFT m.b.H. Medicine with a destructive effect on malignant tumours, process for its manufacture and preparation for use in the therapy of cancer patients
US5021452A (en) * 1989-01-09 1991-06-04 The Board Of Regents Of The University Of Washington Process for enhancing wound healing
US5281196A (en) * 1992-05-22 1994-01-25 Sultenfuss Thomas J Skin treatment composition and method of use
WO1998052560A1 (en) * 1997-05-21 1998-11-26 Sloan-Kettering Institute For Cancer Research Method for increasing the concentration of ascorbic acid in brain tissues of a subject
DE19935763A1 (en) * 1999-07-27 2001-02-08 Volkhard Jenning Retinoid-containing emulsion for topical cosmetic or dermatological use, e.g. in skin regeneration or acne treatment, containing stabilizing combination of ascorbic acid and polyphenol compounds
WO2001015692A1 (en) * 1999-08-30 2001-03-08 Oxycal Laboratories, Inc. Methods and compositions for selective cancer chemotherapy
WO2001037830A1 (en) * 1999-11-24 2001-05-31 Sloan-Kettering Institute For Cancer Research Method for increasing the concentration of ascorbic acid in brain tissues of a subject

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Progenics announces promising results with novel treatment for debilitating cancer therapy side effect", INTERNET ARTICLE, 22 May 2000 (2000-05-22), XP002188668, Retrieved from the Internet <URL:http://www.progenics.com/PR%20Archives%202000/05-22-00%20ASCO.pdf> [retrieved on 20020128] *
BAADER S.L. ET AL: "Uptake and cytotoxicity of ascorbic acid and dehydroascorbic acid in neuroblastoma (SK-N-SH) and neuroectodermal (SK-N-LO) cells.", ANTICANCER RESEARCH, (1994) 14/1 A (221-227)., XP001053256 *
DAWSON RB, HERSHEY RT, MYERS CS, EATON JW: "Blood preservation XLIV. 2,3-DPG maintenance by dehydroascorbate better than D-ascorbic acid", TRANSFUSION, vol. 20, no. 3, 1980, pages 321 - 323, XP001053184 *
DOMKE I ET AL: "REINVESTIGATION OF THE DIABETOGENIC EFFECT OF DEHYDROASCORBIC ACID", INTERNATIONAL JOURNAL FOR VITAMIN & NUTRITION RESEARCH, HOGREFE AND HUBER, BERNE, CH, vol. 53, no. 1, 29 June 1983 (1983-06-29), pages 51 - 60, XP001024236, ISSN: 0300-9831 *
FUJITA K ET AL: "REDUCTION OF ADRIAMYCIN TOXICITY BY ASCORBATE IN MICE AND GUINEA-PIGS", CANCER RESEARCH, vol. 42, no. 1, 1981, pages 309 - 316, XP001053262, ISSN: 0008-5472 *
GERMAIN E ET AL: "Dietary n-3 polyunsaturated fatty acids and oxidants increase rat mammary tumor sensitivity to epirubicin without change in cardiac toxicity.", LIPIDS, vol. 34, no. SUPPL., 1999, 3rd Congress of the International Society for the Study of Fatty Acids and Lipids;Lyon, France; June 1-5, 1998, pages S203, XP001053254, ISSN: 0024-4201 *
ISRAEL RJ ET AL.: "Topical dehydroascorbic acid reduces moderate to severe mucositis in the hamster acute radiation model", AMERICAN SOCIETY OF CLINICAL ONCOLOGY ONLINE, 22 May 2000 (2000-05-22), XP002188669, Retrieved from the Internet <URL:http://www.asco.org/prof/me/html/00abstracts/sm/m_2367.htm> [retrieved on 20020128] *
JONES E, DAVIES JEW, HUGHES, RE: "Tissue ascorbic acid and a liver dehydroascorbatase in guinea-pigs", EXPERIENTIA, vol. 35, no. 5, 1979, pages 303 - 304, XP002179175 *
LOCKWOOD THOMAS D: "Redox-dependent and redox-independent subcomponents of protein degradation in perfused myocardium.", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 276, no. 5 PART 1, May 1999 (1999-05-01), pages E945 - E954, XP002188666, ISSN: 0002-9513 *
MEADOWS G G ET AL: "ASCORBATE IN THE TREATMENT OF EXPERIMENTAL TRANSPLANTED MELANOMA", AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 54, no. 6 SUPPL., 1991, pages 1284S - 1291S, XP001053245, ISSN: 0002-9165 *
PIERSON HF: "Depletion of extracellular cysteine with hydroxocobalamin and ascorbate in experimental murine cancer chemotherapy", CANCER RESEARCH, vol. 45, no. 10, 1985, pages 4727 - 44731, XP001053219 *
POYDOCK M E: "EFFECT OF COMBINED ASCORBIC ACID AND B-12 ON SURVIVAL OF MICE WITH IMPLANTED EHRLICH CARCINOMA AND L1210 LEUKEMIA", AMERICAN JOURNAL OF CLINICAL NUTRITION, BETHESDA,MD, US, vol. 54, no. 6, 1 December 1991 (1991-12-01), pages 1261S - 1265S, XP002060432, ISSN: 0002-9165 *
SUTHERLAND R M ET AL: "POTENTIAL CHEMOTHERAPEUTIC DRUGS WITH SELECTIVE TOXICITY FOR HYPOXIC CELLS.", PROC AM ASSOC CANCER RES, (1976). VOL. 17, PP. 221. ISSN: 0569-2261., Ontario Cancer Foundation, Experimental Oncology, Victoria Hospital, London, Ontario N6A 4G5., XP001053241 *
UPSTON JOANNE M ET AL: "Efflux of hepatic ascorbate: A potential contributor to the maintenance of plasma vitamin C.", BIOCHEMICAL JOURNAL, vol. 342, no. 1, 15 August 1999 (1999-08-15), pages 49 - 56, XP002188667, ISSN: 0264-6021 *
WILLIS R.J. ET AL: "Transport of ascorbic acid in perfused rat lung.", PFLUG.ARCH.EUR.J.PHYSIOL., (1975) 356/1 (93-98). CODEN: PAGPA4, XP001053243 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9308234B2 (en) 2012-10-29 2016-04-12 The University Of North Carolina At Chapel Hill Methods and compositions for treating mucosal tissue disorders

Also Published As

Publication number Publication date
EP1282416A2 (en) 2003-02-12
CA2408562A1 (en) 2001-11-29
AU2001222986A1 (en) 2001-12-03
JP2004514650A (en) 2004-05-20
WO2001089520A2 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
WO2001089520A3 (en) Dehydroascorbic acid formulations and uses thereof
WO2004062625A3 (en) Macrocyclic beta-secretase inhibitors for treatment of alzheimer&#39;s disease
WO2004037193A3 (en) Chromones and chromone derivatives and uses thereof
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2001068135A3 (en) Compositions and methods for affecting osteogenesis
WO2005102392A3 (en) Combinations for treating hiv infection
WO2005018545A3 (en) Macrocyclic beta-secretase inhibitors for the treatment of alzheimer&#39;s disease
MY143795A (en) Tetrahydropyridoindole derivatives
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
IL183953A (en) Method of reducing oxidant induced damage of a food product, a pharmaceutical or stored blood and novel compounds therefor
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer&#39;s disease
WO2006118948A3 (en) Therapeutic compositions
AU2002349352A1 (en) Keratinocytes which may be used as biologically active substances for the treatment of wounds
WO2004056828A3 (en) Novel compounds and uses thereof
HUP0600341A2 (en) Keratinocytes which may be used as biologically active substances for the treatment of wounds
WO2004074232A8 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
TW200503773A (en) Composition for external use
AU3173301A (en) Methods and compositions for treatment of alzheimer&#39;s disease by enhancing plasmin or plasmin-like activity
WO2002070464A3 (en) Hydrazones and their therapeutic use
WO2003018059A3 (en) Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
HK1063290A1 (en) Pharmaceutical formulations containing low concentrations of peroxide for treating or preventing vaginal infections.
WO2003039453A3 (en) Novel benzoyl peroxide compositions for the treatment of dermatological disorders and methods for their use
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
HK1092693A1 (en) Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superfinfections and fungal recurrences

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2408562

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000986812

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000986812

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000986812

Country of ref document: EP